Back to news

Moleculin Strengthens Global Intellectual Property Portfolio Around Annamycin, Secures Korean Patent Allowance

Globe Newswire•18/11/2026•08:35 ET
0

Key Highlights

  • ➤South Korea grants Annamycin reconstitution patent, expanding Moleculin’s international IP estate
  • ➤Moleculin’s Annamycin portfolio spans more than 20 jurisdictions across three technology areas
  • ➤MIRACLE Phase 2/3 trial evaluates Annamycin-cytarabine combination in relapsed/refractory AML
  • ➤Moleculin says additional financing is required to conduct its clinical trials

Expert Statements

Walter Klemp, Chairman and Chief Executive Officer of Moleculin

“This Korean allowance is another building block in a deliberate, multi-year strategy to protect Annamycin around the world and across several layers of the technology.”

Walter Klemp, Chairman and Chief Executive Officer of Moleculin

“We have not relied on a single patent.”

Walter Klemp, Chairman and Chief Executive Officer of Moleculin

“We have built overlapping protection around how Annamycin is formulated, how it is reconstituted and how it can be applied to lung-targeted therapies.”

Walter Klemp, Chairman and Chief Executive Officer of Moleculin

“With Korea now joining Japan, China, Australia, Taiwan, Singapore and other major markets, we believe our global IP position is increasingly robust.”

Walter Klemp, Chairman and Chief Executive Officer of Moleculin

“That matters as we advance our pivotal MIRACLE trial and think about Annamycin’s long-term commercial and partnering potential worldwide.”

Patent protection spans North America, Europe & Asia-Pacific Rim

Korean decision to grant extends reconstitution protection into another key Asia-Pacific market, reinforcing a multi-layered portfolio spanning more than 20 jurisdictions as pivotal Phase 3 MIRACLE trial advances

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in